Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among k ...

点击“蓝字”关注我们近日，ResearchAndMarkets.com发布《GLP-1市场行业趋势和全球预测至2035年，按分子类型、活性成分、GLP-1激动剂药物类型、激动剂类型、给药途径、目标适应症和主要地理区域划分》报告。报告指出，全球GLP- ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

People on Ozempic and other GLP-1 agonist drugs commonly report they no longer have constant, incessant thoughts about food. This is how the drugs work.